Swiss Biotech Company with a Patented Product Seeks Investors for Global Market Entry

The company positions itself as an innovative research center in the field of electric drive technologies in Germany and has its roots in a university spin-off. Specializing in the development of advanced electric motors and its own research projects, it has an extensive patent portfolio comprising 198 intellectual property rights, including three patents with high potential in the automotive/mobility, renewable energy, and industrial sectors. Through technologies that either increase performance or reduce the use of rare earth elements, the company is decreasing dependence on critical raw materials. With strong partnerships in the automotive industry and a team of highly qualified scientists who rank among the top 2% in their fields, it underscores its strategic relevance to buyers operating in a rapidly changing market.

The company specializes in the sustainable and innovative production of microalgae using patented photobioreactor (PBR) technology, which enables continuous, automated production around the clock. With locations in Bavaria and Croatia, it serves target markets such as the pharmaceutical, food, and cosmetics industries by offering high-quality products such as proteins, omega-3 fatty acids, and vitamins. The company’s efficiency, commitment to quality, and growth potential clearly set it apart from the competition, while the space and personnel required for production can be kept remarkably minimal.

Our client is an innovative company in the field of materials testing and inspection. The company has developed a patented 3-in-1 process for testing metals and specializes in the manufacture of advanced testing equipment for measuring mechanical and geometric properties. In addition to stationary devices, mobile and in-line solutions are about to be implemented. Our client also offers a SaaS business model that complements its AI-based material testing and enables promising, recurring revenue. Our client’s technology is already in use at various research institutions, universities, and leading companies in the automotive, aerospace & defense, and metal manufacturing industries. Growth capital will be used to advance research and development and the SaaS business model. It will also enable investments in the company’s workforce.

The company presents itself as a dynamic biotech startup specializing in the development of a topical solution for the treatment of androgenetic alopecia in men. It has reached the significant milestone of securing a patent for its innovative combination of finasteride and minoxidil in 37 countries. In addition to its exclusive formulation, the company possesses complete manufacturing specifications as well as all necessary rights and utility models from Germany. With its clearly defined, ready-to-go product, the company is at a critical growth juncture with high global scaling potential in a market valued at 35 billion euros.

The company positions itself as a pharmaceutical importer with over a decade of market presence and an extensive customer base throughout Germany. It is characterized by stable supply chains and offers a diverse pharmaceutical portfolio. A significant competitive advantage stems from its first-class service offerings and existing approvals, which have enabled the company to successfully position itself in the B2B sector—primarily with wholesale partners and pharmacies—as well as in contract manufacturing, including refrigerated products. In addition, framework and discount agreements with key players in the healthcare sector strengthen the company’s growing market position.